	US 7,485,697 B2
	Soluble rage protein
Hiroshi Yamamoto, Kanazawa (Japan); Hideto Yonekura, Kanazawa (Japan); Yasuhiko Yamamoto, Takaoka (Japan); Shigeru Sakurai, Kanazawa (Japan); and Takuo Watanabe, Kanazawa (Japan)
Assigned to Japan as Represented by President of Kanazawa University, Ishikawa (Japan)
Appl. No. 10/472,507 PCT Filed Mar. 19, 2002, PCT No. PCT/JP02/02623 § 371(c)(1), (2), (4) Date May 12, 2004, PCT Pub. No. WO02/074805, PCT Pub. Date Sep. 26, 2002.
Claims priority of application No. 2001-078409 (JP), filed on Mar. 19, 2001; application No. 2001-243114 (JP), filed on Aug. 10, 2001; and application No. 2002-048182 (JP), filed on Feb. 25, 2002.
Prior Publication US 2005/0033017 A1, Feb. 10, 2005
Int. Cl. C07K 14/705 (2006.01); C07H 21/04 (2006.01); C12P 21/02 (2006.01); G01N 33/53 (2006.01); C12Q 1/68 (2006.01)

U.S. Cl. 530—350 [435/6; 435/7.1; 435/69.1; 435/252.3; 435/254.11; 435/320.1; 435/325; 536/23.5]

1 Claim

1. An isolated soluble polypeptide comprising:

(a) the amino acid sequence described in SEQ ID NO:2 of the sequence listing; or

(b) an amino acid sequence having at least 97% homology with the amino acid sequence described in SEQ ID NO:2 of the sequence listing, and comprising from 1 to 16 amino acids of Glu³³²to Met³⁴⁷of the amino acid sequence described in SEO ID NO:2 of the sequence listing at the C-terminus;

wherein the soluble polypeptide has Advanced Glycation Endproducts (AGE) binding activity.